Recombinant E.coli lasA Protein，His

LasA is a lysin derived from Pseudomonas aeruginosa, a significant opportunistic pathogen associated with various infections, especially in immunocompromised individuals. Understanding LasA and its recombinant forms has garnered substantial attention due to its potential therapeutic applications, particularly in combating antibiotic-resistant bacterial strains. Research on LasA has focused on its role in bacterial cell wall lysis, as it exhibits endopeptidase activity that specifically targets the peptidoglycan layer, promoting cell death in Gram-positive bacteria. Recombinant protein technology has enabled the production of LasA in heterologous systems, facilitating detailed studies of its structure-function relationships and enhancing its potential application in biomedicine. The ability to engineer LasA variants with improved stability and efficacy has opened avenues for developing novel antimicrobial agents, offering alternative treatment strategies against P. aeruginosa infections and other resistant pathogens. Additionally, understanding the mechanisms by which LasA interacts with bacterial cell walls contributes to the broader field of antibacterial drug development and resistance mitigation. Overall, the research on LasA recombinant proteins stands at the intersection of microbiology, biochemistry, and therapeutic development, addressing the urgent need for new antimicrobial solutions in the face of rising resistance challenges.